Beam Therapeutics Inc.

Cash Runway Beam expects that its cash, cash equivalents and marketable securities as of June 30, 2025, will enable the company to fund its anticipated operating expenses and capital expenditure requirements into 2028.

SEC original ↗Beam Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

In February 2026, the Company entered into a financing agreement with certain lenders and Sixth Street Lending Partners which provides for a credit facility, or the Credit Facility, consisting of an initial draw of $ 100.0 million on the closing date; up to $ 300 million available upon the achievement of certain clinical, regulatory and commercial milestones for risto-cel; and an additional $ 100 million available at the Company s option, subject to mutual agreement between the parties, during the seven-year term of the agreement.

SEC original ↗Beam Therapeutics Inc. — 10-Q Quarterly report10-QAug 4, 2026

The Credit Facility matures on February 24, 2033 and bears interest at an annual rate equal to the 3-month Secured Overnight Financing Rate (SOFR) plus 6.5 % (subject to a 1.00 % floor).

SEC original ↗Beam Therapeutics Inc. — 10-Q Quarterly report10-QAug 4, 2026

Certain additional commitment, administrative, undrawn amount and facility fees are also payable in connection with the Credit Facility.

SEC original ↗Beam Therapeutics Inc. — 10-Q Quarterly report10-QAug 4, 2026

Until such time as the Company can generate 7 significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements.

SEC original ↗Beam Therapeutics Inc. — 10-Q Quarterly report10-QAug 4, 2026

Since the date of those financial statements, except as set forth below under Debt, there have been no material changes to the Company's significant accounting policies.

SEC original ↗Beam Therapeutics Inc. — 10-Q Quarterly report10-QAug 4, 2026

“In the first half of 2025, we made significant clinical, operational and regulatory progress across each of our high-priority programs, and we aim to harness this momentum heading into key catalysts at the end of 2025 and early next year,” said John Evans, chief executive officer at Beam.

SEC original ↗Beam Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs.

SEC original ↗Beam Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

The Company will need additional financing to support its continuing operations and pursue its growth strategy.

SEC original ↗Beam Therapeutics Inc. — 10-Q Quarterly report10-QAug 4, 2026

Until such time as the Company can generate 7 significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements.

SEC original ↗Beam Therapeutics Inc. — 10-Q Quarterly report10-QAug 4, 2026

The inability to raise capital as and when needed would have a negative impact on the Company s financial condition and its ability to pursue its business strategy.

SEC original ↗Beam Therapeutics Inc. — 10-Q Quarterly report10-QAug 4, 2026

All of these statements are subject to known and unknown important risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements.

SEC original ↗Beam Therapeutics Inc. — 10-Q Quarterly report10-QAug 4, 2026

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Risk Factors in Part II, Item 1A of this Quarterly Report on Form 10-Q and Risk Factors Summary and Risk Factors in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, or the 2025 Form 10-K.

SEC original ↗Beam Therapeutics Inc. — 10-Q Quarterly report10-QAug 4, 2026

Legal Proceedings 35 Item 1A.

SEC original ↗Beam Therapeutics Inc. — 10-Q Quarterly report10-QAug 4, 2026

The Company is subject to risks and uncertainties common to clinical-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations.

SEC original ↗Beam Therapeutics Inc. — 10-Q Quarterly report10-QAug 4, 2026

The value attributable to sublicenses and the related sublicense fees due under the Company s license agreements may require estimates and other judgments related to contractual requirements, which creates uncertainty over the ultimate amount that would be paid under these arrangements.

SEC original ↗Beam Therapeutics Inc. — 10-Q Quarterly report10-QAug 4, 2026